2023.7.7

We have decided to relocate to the International Hub for Healthcare Innovation,

The International Hub for Healthcare Innovation is an institution operated by the Organization for Advanced Healthcare Innovation (Headquarters: Osaka City,Osaka; Chair, Yoichi Honma). Its primary objective is to promote the industrialization of latest innovations in healthcare, and advance global contributions by providing a platform for healthcare innovation. The institution serves as an industrial base where hospitals offering the latest healthcare innovations, including regenerative medicine, genomic medicine, and AI diagnosis, and companies such as ventures and support organizations engaged in the development of such innovations, come together under the same roof. Therefore, we have decided to move into the hub liaison office with the objective of further advancing our research and development.

We are committed to closely collaborate with the stakeholders involved in the latest healthcare innovations within the hub, and will strive to contribute to industrialization of advanced healthcare technologies.

International Hub for Healthcare Innovation
→ https://miraikiko.jp/base/

2022.4.4

The group, led by Professor Koji Nishida (Ophthalmology), Graduate School of Medicine, Faculty of Medicine, Osaka University, commenced clinical research to transplant corneal epithelial cell sheets, prepared from human allogeneic iPS cells, into patients with limbal stem cell deficiency in 2019. It held a press conference to announce that the results obtained demonstrated safety and efficacy.

Graduate School of Medicine, Faculty of Medicine, Osaka University Press Release
→ https://www.med.osaka-u.ac.jp/archives/29591

Based on the results of this clinical study, we will continuously prepare for clinical trials to launch human iPS cell-derived regenerative medicine products

2022.2.14

We would like to announce that we have participated in “P.S. i LOVE YOU PROJECT,” along with the Center for iPS Cell Research and Application, Kyoto University (CiRA_F), and companies that use iPS cell stocks of CiRA_F, or conduct joint research with CiRA_F, in order to make iPS cell-based regenerative medicine commonly available, and to generate awareness and interest about it among general public.

“P.S. i LOVE YOU PROJECT”

It has been 15 years since the establishment of human iPS cells was reported in a paper.
Efforts have been made to develop next-generation iPS cells to resolve issues related to quality, time, and cost, thereby enabling widespread use of iPS cell-based treatment in society and the medical field.
To make this iPS cell-based regenerative medicine commonly available, it is necessary for academia and industry to collaborate and address various matters, and to generate interest and understanding for it among the general public. Therefore, a campaign was initiated on Valentine’s Day, wherein CiRA_F and the participating companies shared their thoughts on iPS cell-based regenerative medicine.

Please visit the website of “P.S. i LOVE YOU PROJECT” for further information.
→ 『P.S. i LOVE YOU　PROJECT』

2019.8.29

The group led by Professor Koji Nishida (Ophthalmology), Graduate School of Medicine, Faculty of Medicine, Osaka University, announced in July 2019, that corneal epithelial cell sheets prepared from human allogeneic iPS cells were transplanted into a patient with limbal stem cell deficiency. Professor Nishida has developed our core technology, the SEAM method (R. Hayashi et al., Nature 2016), which recreates two-dimensionally induced eye-related cells simultaneously, including the cornea and retina. This clinical research plan was approved by the Ministry of Health, Labour, and Welfare in March 2019, and the study was initiated. Following this case of transplantation, the transplantation of iPS cell-derived corneal epithelial cell sheets into the 2nd patient is scheduled by the end of this year.
In parallel with this clinical research, we are conducting clinical trials to launch human iPS cell-derived regenerative medicine products.
Japan Agency for Medical Research and Development HP press release

→ https://www.amed.go.jp/news/release_20190829.html

2019.3.5

Our core technology, the SEAM method (R. Hayashi et al., Nature 2016), which recreates two-dimensionally induced eye-related cells simultaneously, including the cornea and retina, is an innovative technology developed by a group at the Graduate School of Medicine, Faculty of Medicine, Osaka University, led by Professor Koji Nishida (Ophthalmology), the founder of the Company. Professor Nishida et al. prepared corneal epithelial cell sheets, using human induced pluripotent stem cells (iPS cells), and submitted a clinical research plan (Class I regenerative medicine provision plan) to graft them into patients with corneal diseases for regeneration, to the Ministry of Health, Labour and Welfare on January 16, 2019. The plan was conditionally approved, based on a review by the Committee on Regenerative Medicine, Health Science Council of the Ministry of Health, Labour, and Welfare, at a meeting held on March 5, 2019.
In this clinical research, corneal epithelial cells, induced from iPS cells of other people, provided by the Center for iPS Cell Research and Application, Kyoto University, will be cultured in a sheet form, and grafted into four patients with limbal stem cell deficiency.

→ https://www.med.osaka-u.ac.jp/archives/16246

2018.2.26

Website was launched.